| Assessment Status |
Rapid Review Complete |
| HTA ID |
26034 |
| Drug |
Evinacumab |
| Brand |
Evkeeza® |
| Indication |
Evinacumab (Evkeeza®) as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and paediatric patients aged 6 months and older with homozygous familial hypercholesterolaemia (HoFH). |
| Rapid review commissioned |
08/07/2026 |
| Rapid review completed |
30/07/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of evinacumab (Evkeeza®) compared with the current standard of care. |
